drugset
drugset / Trial / NCT07414602

A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects

NCT07414602 ↗

Phase 1 Recruiting 40 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Phase I clinical study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1894 in healthy subjects.

Timeline

Start
2026-03-16
Primary completion
2026-10
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1894 Unknown — Subcutaneous

Indications

dermatitis